Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease

Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease

Abstract Background Metabolic dysfunction associated steatotic liver disease (MASLD) is prevalent in up to 60% of patients with type 2 diabetes mellitus (T2DM). T2DM accelerates the risk of hepatic fibrosis and hepatocellular carcinoma in patients with MASLD. Our goal in this study was to identify p...

Full description

Bibliographic Details
Main Authors: Ahmed Ebeid, Fatma Mokhtar, Valeria Martinez-Lebron, Susie Park, Seta Degann, Jeremy Payano, Zahid Vahora, Stephen Gray, Lynt Johnson, Diala El-Maouche, Ameer Abutaleb
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Endocrine Disorders
Subjects:
Metabolic dysfunction associated steatotic liver disease (MASLD)
MASH
Fibrosis scoring systems
Non-invasive tests
Advanced liver fibrosis
Online Access:https://doi.org/10.1186/s12902-025-01881-9

Internet

https://doi.org/10.1186/s12902-025-01881-9

Similar Items